OncoMatch/Clinical Trials/NCT07354711
A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors
Is NCT07354711 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies 3H-10000 for lung cancer.
Treatment: 3H-10000 — The study is being conducted to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of 3H-10000 in the treatment of unresectable or metastatic solid tumors .
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Gastric Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: investigational drug
Having received treatment with other investigational drugs within 4 weeks prior to the first dose of the study drug.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07354711 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior investigational drug disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify